Prospective, randomized and controlled study of the efficacy of rabeprozole and placebo in the treatment of nonerosive reflux disease.

DSpace/Manakin Repository

Prospective, randomized and controlled study of the efficacy of rabeprozole and placebo in the treatment of nonerosive reflux disease.

Show full item record

Title: Prospective, randomized and controlled study of the efficacy of rabeprozole and placebo in the treatment of nonerosive reflux disease.
Author: Hakim, M. Shafi (Scholar); Zargar, Showkat A (Guide); Shah, Altaf H (Guide); Gul Javid (Guide); Khan, B. A (Guide); Yatoo, G. N (Guide); Gulzar, G. M (Guide); Sodhi, J. S (Guide); Khan, M. A (Guide); Bilal-u-Rehman (Guide); Shah, N. A (Guide); Zeeshan Asif Iqbal (Guide)
Abstract: Background: Nonerosive reflux disease is defined as the presence of typical symptoms of gastroesophageal reflux disease in absence of visible esophageal mucosal injury at endoscopy. 24 hour ph study is needed to define the sub group. Treatment with the acid inhibitory agents is effective, proton pump inhibitors are most effective form of therapy. Clinical results to date suggest that anti-secretory therapy may be less effective in providing symptom relief for the patients nonerosive reflux disease than the patients with erosive disease. Objective: To assess prospectively effectiveness of proton pump inhibitors in nonerosive reflux disease Methods: A total of 200 patients with nonerosive reflux disease were randomized to receive placebo (98) or rabeprozole (102) for 6 months, with consultations at 3 weeks, 6 weeks, and 6 months. The primary end points were change in the severity of heart burn and regurgitation at the above mention periods. Results: Demographics of the randomized in each group were comparable except that placebo group included more males. The baseline characteristics between two groups were similar. After 6 month of treatment, reduction of visual analogue scale (VAS) of heartburn was prominent in treatment group (63% vs. 15%). At 3 weeks and six weeks, treatment group showed greater reduction of VAS for heart burn (p<0.01). Patients of the treatment group had lower frequency of heartburn (p<0.01) and regurgitation (p<0.01) at the end of the 6 month treatment. For the adverse effects, there was no difference in the both groups. Conclusions: Rabeprozole was more effective than placebo of the treatment of symptoms presented by the patients with nonerosive reflux disease, who had positive 24 hour ph study.
URI: http://dspaces.uok.edu.in/handle/1/841
Date: 2009


Files in this item

Files Size Format View
28.doc 33Kb Microsoft Word View/Open

This item appears in the following Collection(s)

Show full item record

Search DSpace


Advanced Search

Browse

My Account